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ABSTRACT 
 
Enantio- and diastereoselective hydrogenation of β-keto-γ-lactams with a ruthenium–BINAP catalyst, involving a 
dynamic kinetic resolution (DKR), has been employed to provide a general, asymmetric approach to β-hydroxy-γ-
lactams, a structural motif common to several bioactive compounds. Full conversion to the desired β-hydroxy-γ-
lactams was achieved with high diastereoselectivity (up to >98% de) by addition of catalytic HCl and LiCl, while β-
branching of the ketone substituent demonstrated a pronounced effect on the modest to excellent enantioselectivity 
(up to 97% ee) obtained. 
The generation of contiguous stereogenic centres from 
racemic or achiral starting materials in a selective fashion 
is a standing ambition of asymmetric synthesis. Dynamic 
kinetic resolution (DKR) is a powerful methodology 
which enables the necessary two supplementary steps: 
racemisation together with a consecutive asymmetric 
transformation.1 In pursuit of a synthetic approach for 
access to multigram quantities of two serotonin 
norepinephrine reuptake inhibitors (SNRIs) 5 and 6, a 
route (Scheme 1) was developed by Magnus and 
coworkers at Lilly which employed a DKR involving the 
enantio- and diastereoselective hydrogenation of a β-
keto-γ-lactam 3a,2 based on the chemistry precedented by 
Takasago International Corporation.3a The optimised 
DKR-hydrogenation afforded the critical β-hydroxy-γ-
lactam 4a in high yield (93%) and with impressive 
stereocontrol (96% ee, 94% de).  
Given the remarkable success of this reaction, in 
furnishing a single product, in high yield and excellent  
enantiomeric and diastereomeric excess, and the paucity 
of known examples for similar substrates,3a-c we wished 
to explore the scope of the transformation, with the 
ultimate aim of establishing the route as a general 
pathway to optically pure β-hydroxy-γ-lactams. The β-
hydroxy-γ-lactam structure provides a viable precursor to 
compounds containing a pyrrolidine moiety, an important 
pharmacophore in many biologically active molecules. 
The motif is present in compounds exhibiting diverse 
pharmacological effects, ranging from antimicrobial and 
antifungal activity3 to serotonin norepinephrine reuptake 
inhibition,4 making a general asymmetric approach to β-
hydroxy-γ-lactams—and any pyrrolidine-containing 
compounds derived thereafter—a desirable objective in 
its own right. 
 
Scheme 1. DKR-Hydrogenation-based Synthesis of SNRIs 5 and 6 
 
 
 To evaluate substrate scope of the transformation, nine 
novel β-keto-γ-lactams 3b-e and 7a-e (Figure 1) were 
prepared for investigation, alongside the model 
compound 3a used by Lilly. The substrates comprized 5 
pairs, where each of the pair was differentiated by the 
presence or absence of a methylene functionality adjacent 
to the ketone. This enabled the importance of branching 
at the β-position to be comprehensively assessed, with 
respect to both substrate conversion and stereochemical 
outcome. 
 
Figure 1.  β-Keto-γ-Lactams for Substrate Study  
 
 
 
All β-keto-γ-lactams 3a-e and 7a-e were prepared via 
Claisen-type condensations, using N-benzyl-γ-lactam 1 
and the appropriate ester (Table 1). In most cases, 
cryogenic conditions (–75 °C) were employed, though a 
modified protocol, used for preparation of  the original 
substrate 3a,2 could also be implemented for synthesis of 
β-keto-γ-lactams 3e and 7c. The latter procedure allowed 
the reactions to be run at –10 to 5 °C and took advantage 
of the insolubility of the intermediate enolate, which was 
isolated from the reaction mixture by filtration prior to 
acidic workup, and rendered subsequent chromatographic 
purification a trivial endeavour. The reduced yield of 
compound 7c (Table 1, entry 6) was due to inefficient 
enolate precipitation, however, as sufficient material for 
this study was recovered, the reaction was neither 
repeated nor optimized. 
 
 
 
Table 1. Claisen-type Synthesis of β-Keto-γ-Lactams 1 
  
 aMethod A involved addition of a mixture of γ-lactam 1 and the 
ester to a solution of LDA in 2-MeTHF at –10 to 5 °C with 
subsequent addition of heptane to precipitate the intermediate 
enolate of β-keto-γ-lactam 3, the precipitate was collected, 
suspended in MTBE, and worked-up with 10% aq citric acid; 
Method B involved pre-generation of the enolate of γ-lactam 1, 
as a solution in THF at –75 °C, to which the ester was added 
slowly. bIsolated yield after chromatography on silica gel.  
Each of the substrates 3a-e and 7a-e was then 
subjected to the key Noyori-type reduction, under 
conditions previously optimized for 3a, to investigate if 
the methodology developed for 3a could be generally 
applied. Ruthenium-catalyzed hydrogenations were 
conducted using methanol, ethanol or IPA as solvent, and 
in the presence of catalytic HCl and LiCl as additives 
(Table 2). 
entry n R methoda product (% yield)b 
1 1 i-propyl A 3a (65) 
2 0 i-propyl B 7a (68) 
3 1 cyclopropyl B 3b (63) 
4 0 cyclopropyl B 7b (66) 
5 1 cyclohexyl B 3c (41) 
6 0 cyclohexyl A 7c (34) 
7 1 phenyl B 3d (69) 
8 0 phenyl B 7d (48) 
9 1 t-butyl A 3e (66) 
10 0 t-butyl B 7e (61) 
 
Table 2. DKR-Hydrogenation Substrate Screen 
 
 aScreening reactions run with β-keto-γ-lactam 3 or 7 (1 g), diacetato[(S)-(−)-2,2′-bis(di-p-tolylphosphino)-1,1′-binaphthyl]ruthenium(II) 
(Ru(OAc)2[(S)-tol-BINAP)])5 (substrate to catalyst mole ratio (S/C): 280), HCl (6 mol%), and solvent (55 mL) at 65 °C under 85–90 psi of 
H2. bMole percent relative to substrate 3 or 7. cExtent of reaction as determined by 1H NMR analysis. dDetermined by chiral HPLC (see 
SI). eNot applicable (too small to accurately measure). fReactions in IPA were run at a concentration of  88 mg/mL (4.4 g of substrate 3 or 
7) as a dilution effect caused ineffective hydrogenation at the lower concentration employed when using other solvents. gSecond charge of 
catalyst (S/C: 280) was added after 16 h. hThis reaction was repeated with a value of 8.3% ee recorded. 
While the use of HCl in Noyori-type reductions is 
heavily precedented,6 use of LiCl as an additive had also 
been established as a critical component of the catalyst 
system for hydrogenations performed in IPA; its presence 
was found to be essential for reliable conversion of 3a to 
the corresponding β-hydroxy-γ-lactams (±)-4/9a.2 LiCl 
has previously been shown to enhance the reactivity of 
ruthenium–BINAP catalytic systems.7 Thus, with a view 
to generalizing the reaction, LiCl was included as an 
additive for each substrate undergoing hydrogenation in 
IPA, though in some instances it is not necessarily 
required—as indicated by the complete conversion of the 
isopropyl substrate 7a in its absence. Effective 
stereoselective hydrogenation of most of the substrates 
3a-e and 7a-e was achieved, as summarised in Table 2, 
with the corresponding products obtained in good 
isolated yields (83–92%). While reactions were slightly 
slower on going from methanol/ethanol to IPA, overall, 
the enantioselectivity was in general slightly higher for 
reactions conducted in IPA. 
The presence of a bulky t-butyl group, adjacent to the 
site of hydrogenation in substrates 3e and 7e, essentially 
blocked reduction of these compounds (Table 2, entries 3, 
8, 9 and 10). Interestingly, variation of the steric (MeOH 
cf. EtOH) and electronic properties (trifluoroethanol, pKa 
12.4 cf. EtOH, pKa 15.9)8 of the solvent had virtually no 
impact on the extent of hydrogenation observed in these 
challenging substrates. Hydrogenation of 3e and 7e in 
IPA was not attempted, as hydrogenation in this solvent 
is more challenging across all susbtrates, often requiring a 
second charge of catalyst and prolonged reaction times. 
The use of LiCl as an additive in reactions of 3e and 7e in 
ethanol was also ineffective (Table 2, entry 9), and so 
was deemed unlikely to have an impact with IPA. 
    n = 1  n = 0 
entrya R LiClb solvent substrate 
(product) 
Time (%c) % 
eed 
% ded  substrate 
(product) 
Time (%c) % eed % ded 
1 i-propyl 0 MeOH 3a (4a) 16 h 93.6 90.2  7a (8a) 16 h 78.7 >98.0 
2 cyclohexyl 0 MeOH 3c (4c) 16 h  94.5 96.5  - - - - 
3 t-butyl 0 MeOH 3e (4e) 16 h (<2.0) 39.0 NAe  - - - - 
4 i-propyl 0 EtOH 3a (4a) 16 h 94.3 94.4  7a (8a) 16 h 74.6 88.7 
5 cyclopropyl 0 EtOH 3b (4b) 16 h 84.2 97.5  7b (8b) 16 h 96.8 95.8 
6 cyclohexyl 0 EtOH 3c (4c) 16 h 95.0 94.7  7c (8c) 16 h 35.5 >98.0 
7 phenyl 0 EtOH 3d (4d) 16 h 84.7 91.6  7d (8d) 16 h 18.2 >98.0 
8 t-butyl 0 EtOH 3e (4e) 16 h (<2.0) 63.9 NAe  7e (8e) 16 h (<2.0) NAe NAe 
9 t-butyl 1 EtOH 3e (4e) 16 h (<2.0) NAe NAe  7e (8e) 16 h (<2.0) NAe NAe 
10 t-butyl 0 CF3CH2OH 3e (4e) 16 h (<2.0) 42.1 NAe  - - - - 
11 i-propyl 0 IPAf - - - -  7a (8a) 16 h 72.1 >98.0 
12 i-propyl 1 IPAf 3a (4a) 16 h (63.5) - -  7a (8a) 16 h 67.1 93.4 
     36 hg 96.5 95.6      
13 cyclopropyl 1 IPAf 3b (4b) 16 h 86.1 >98.0  7b (8b) 16 h 94.9 92.6 
14 cyclohexyl 1 IPAf 3c (4c) 16 h (95.4) - -  7c (8c) 16 h 38.5 >98.0 
     32 hg 97.4 96.2      
15 phenyl 1 IPAf 3d (4d) 16 h (75.1) - -  7d (8d) 16 h 15.3h >98.0 
     36 hg 87.5 97.0      
While diastereocontrol was excellent across both series 
of substrates 3 and 7, the presence of β-branching in 
substrates 3 was found to have a profound impact on the 
enantioselectivity of the reactions. Thus, hydrogenation 
of substrates 3, which possessed a methylene linker, 
resulted in higher enantioselectivities (>85% ee, other 
than for 3e with t-butyl, where the extent of reaction was 
negligible) than the analogous substrates 7 (15–97% ee).  
Given the unusually low enantioselectivity observed in 
the case of the phenyl substrate 7d (Table 2, entries 7 and 
15), it seemed prudent to investigate if racemization of 
the product might occur during the reaction, although the 
retention of excellent levels of diastereocontrol suggested 
otherwise. Formation of a benzylic carbocation (under the 
acidic reaction conditions employed), or, alternatively, a 
reversible hydride transfer from the ruthenium catalyst 
could potentially be envisaged. When an enantioenriched 
sample of (±)-8/10d (15.2% ee), from the initial reduction 
of 7d in IPA, was re-subjected to the hydrogenation 
conditions for a further 72 h, only a minor decrease in the 
enantiopurity of the material (11.7% ee) was observed, 
suggesting the decreased enantioselectivity of the process 
is not related to stereochemical scrambling in the reaction 
mixture.  Also, the corresponding deuterated β-hydroxy-
γ-lactam 11d was prepared and similarly underwent the 
hydrogenation conditions in IPA for 72 h (Scheme 2), 
without any evidence for deuterium–hydrogen exchange, 
or a change in diastereomeric ratio of the material. 
Accordingly, it appears that the intrinsic enantiocontrol in 
the reduction of the phenyl substrate 7d is genuinely 
significantly lower than that of most other substrates 
explored.  
 
Scheme 2. Preparation and hydrogenation of Deuterated  
  β-Hydroxy-γ-Lactam 11d 
  
In line with precedent,2 the stereochemistry of 4c and 
4d was determined unambiguously to be 3-R, 1′-S by 
single crystal X-ray diffraction using Cu Kα radiation. 
The individual crystals used for X-ray diffraction were 
grown from enantioenriched samples of 4c and 4d (Table 
2, entries 6 and 15), with the stereochemical identity of 
each crystal subsequently confirmed by chiral HPLC 
analysis following the crystallographic work. The 
stereochemistry of the other β-hydroxy-γ-lactam 
derivatives was assigned by inference from these results, 
with the major enantiomer in all cases displaying the 
characteristic features of the appropriate (R*, S*) 
diastereomer in their 1H NMR spectra. The appearance of 
the C-3H signal as a characteristic triplet or triplet of 
doublets at ca. 2.80 ppm was the key distinguishing 
feature of this diastereomer, with the C-3H signal of the 
(R*, R*) diastereomer appearing as an apparent quartet at 
ca. 2.50 ppm. 
In summary, the asymmetric DKR-hydrogenation 
strategy to generate β-hydroxy-γ-lactams was found to be 
generally applicable across a range of substrates, other 
than those with the sterically demanding t-butyl group 
close to the site of hydrogenation. The stereochemical 
outcome, in terms of enantiocontrol, is moderately 
dependent on the solvent employed, while strongly 
substrate dependent, with the best results generally seen 
for -branched substrates 3. Excellent diastereocontrol 
was seen in almost all instances.  
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